Bisphosphonates, specifically Zometa, is commonly used in the treatment of men with advanced prostate cancer. Zometa is used to treat and protect bones from developing fractures. Bisphosphonates are potent inhibitors of bone resorption. Additionally, in vitro studies show that zolendronic acid also inhibits prostate cancer cell growth by activating apoptosis (A form of cell death [...]
The Washington Post has written an article about the funding controversy surrounding the Department of Defense (DOD) Medical Research Programs. I urge everyone to go to the web site and add your comments. Members of congress do read the Washington Post daily. Please go to: The Washington Post It would be a good idea if [...]
Researchers at the Medical Oncology Unit, University of Siena, Viale Bracci 11, 53100, Siena, Italy performed a randomized phase II study which compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the standard of care D/prednisone (P) in men with advanced castrate-resistant prostate cancer (CRPC). […]
Tomorrow, Wednesday- March 2, I will be joining Dr. Daniel Petrylak for a number of radio interviews about prostate cancer. Dr. Petrylak is a world renowned prostate cancer researcher and clinician. He was the principal investigator in for the development of Taxotere (docetaxel). I anticipate that we will cover a number of different prostate cancer [...]
Researchers wanted to determine if concurrent the development of morbidity issues ( i.e.- myocardial infarction, congestive heart failure, angina, diabetes, stroke, circulation problems, inflammatory bowel disease, or amputation) is associated with treatment regret among men with PSA recurrence following failed primary therapy for prostate cancer. The researchers evaluated 795 men from the Comprehensive, Observational, Multicenter, [...]
An article appearing today the Urology Times E-News rang a warning bell about the use of the angiogenesis inhibitor bevacizumab (Avastin). The article warned that men with advanced prostate cancer may be at an increased risk of treatment-related death when bevacizumab is used in combination with other therapies. Senior author Shenhong Wu, MD, PhD, and [...]
The researchers took a cohort of 430 men with a biochemical recurrence (PSA increase only) after failed prostatectomy. The men underwent observation until they experienced metastatic disease as determined by CT or bone scan. The researchers then evaluated the PSA at the time the men developed metastasis for those patients who developed metastatic disease. PSA [...]
Prostate cancer diets and the use of supplements have continued to be an issue faced by men fighting advanced prostate cancer. Different products seem to fall in and out of vogue; unfortunately we usually have little actual hard data on the real value of any of these products. The use of pomegranate with the goal [...]
Yesterday the Prostate Cancer Foundation (PCRF) made a major announcement, it has sequenced the of whole cancer genomes of seven different men with aggressive prostate cancer. This is a historic development in the fight against prostate cancer, however, it is a small step for those of us on the ground. The eventual goal of projects [...]
A recent study conducted at the Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA by the Section of Hematology and Medical Oncology, Tulane University School of Medicine, New Orleans, LA, evaluated the efficacy of the timely use of zoledronic acid (ZA) on clinical outcomes and health care utilization in men with bone-metastatic prostate [...]
